{"id":"https://openalex.org/W4362425609","doi":"https://doi.org/10.1158/1078-0432.22439449.v1","title":"Supplementary Table 1 from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers","display_name":"Supplementary Table 1 from Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4362425609","doi":"https://doi.org/10.1158/1078-0432.22439449.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22439449.v1","doi":"https://doi.org/10.1158/1078-0432.22439449.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22439449.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Autocrine_Production_of_Amphiregulin_Predicts_Sensitivity_to_Both_Gefitinib_and_Cetuximab_in_i_EGFR_i_Wild-type_Cancers/22439449/1/files/39890284.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Autocrine_Production_of_Amphiregulin_Predicts_Sensitivity_to_Both_Gefitinib_and_Cetuximab_in_i_EGFR_i_Wild-type_Cancers/22439449/1/files/39890284.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040004004","display_name":"Kimio Yonesaka","orcid":"https://orcid.org/0000-0002-0816-5315","observed_orcids":["https://orcid.org/0000-0002-0816-5315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimio Yonesaka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035687326","display_name":"Kreshnik Zejnullahu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kreshnik Zejnullahu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035004148","display_name":"Neal Ian Lindeman","orcid":"https://orcid.org/0000-0002-7092-6859","observed_orcids":["https://orcid.org/0000-0002-7092-6859"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neal Lindeman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068870619","display_name":"Alison J. Homes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alison J. Homes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110519","display_name":"David Michael Jackman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David M. Jackman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100401227","display_name":"Feng Zhao","orcid":"https://orcid.org/0000-0001-9850-9718","observed_orcids":["https://orcid.org/0000-0001-9850-9718","https://orcid.org/0000-0001-8017-0242"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Feng Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072085302","display_name":"Andrew M. Rogers","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew M. Rogers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053521833","display_name":"Bruce Evan Johnson","orcid":"https://orcid.org/0000-0002-5252-3677","observed_orcids":["https://orcid.org/0000-0002-5252-3677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce E. Johnson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5048675362","display_name":"Pasi Antero Janne","orcid":"https://orcid.org/0000-0002-7821-4928","observed_orcids":["https://orcid.org/0000-0002-7821-4928"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pasi A. Ja\u0308nne","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.03009999915957451,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amphiregulin","display_name":"amphiregulin","score":0.9919999837875366},{"id":"https://openalex.org/keywords/autocrine-signaling","display_name":"autocrine signaling","score":0.9039999842643738},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.8939999938011169},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.703000009059906},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C2780806702","wikidata":"https://www.wikidata.org/wiki/Q14866198","display_name":"Amphiregulin","level":4,"score":0.9366175532341003},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9126877188682556},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.757372260093689},{"id":"https://openalex.org/C128240485","wikidata":"https://www.wikidata.org/wiki/Q786998","display_name":"Autocrine signalling","level":3,"score":0.515303373336792},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4957157373428345},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4183005094528198},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3982386887073517},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39232751727104187},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.27977028489112854},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.18646761775016785},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.1629575490951538},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.12400269508361816}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.22439449.v1","doi":"https://doi.org/10.1158/1078-0432.22439449.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22439449.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Autocrine_Production_of_Amphiregulin_Predicts_Sensitivity_to_Both_Gefitinib_and_Cetuximab_in_i_EGFR_i_Wild-type_Cancers/22439449/1/files/39890284.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22439449","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Autocrine_Production_of_Amphiregulin_Predicts_Sensitivity_to_Both_Gefitinib_and_Cetuximab_in_i_EGFR_i_Wild-type_Cancers/22439449","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22439449.v1","doi":"https://doi.org/10.1158/1078-0432.22439449.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22439449.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_1_from_Autocrine_Production_of_Amphiregulin_Predicts_Sensitivity_to_Both_Gefitinib_and_Cetuximab_in_i_EGFR_i_Wild-type_Cancers/22439449/1/files/39890284.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362425609.pdf","grobid_xml":"https://content.openalex.org/works/W4362425609.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2103674109","https://openalex.org/W2065766894","https://openalex.org/W89281725","https://openalex.org/W1561412036","https://openalex.org/W1994841376","https://openalex.org/W1967698512","https://openalex.org/W1968282664","https://openalex.org/W1966428098","https://openalex.org/W2054720651","https://openalex.org/W2094962167"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"8K":[3]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2025-10-10T00:00:00"}